Richard F.  Wallman net worth and biography

Richard Wallman Biography and Net Worth

Richard F. Wallman served as the Senior Vice President and Chief Financial Officer of Honeywell International, Inc., a diversified technology company, and AlliedSignal, Inc. (prior to its merger with Honeywell). He is also a member of the boards of directors of Roper Technologies, Inc., Wright Medical Group, Inc., Boart Longyear Limited and Extended Stay America, Inc. He previously served as a member of the board of Convergys Corporation. Mr. Wallman has been a director since January 2011.

What is Richard F. Wallman's net worth?

The estimated net worth of Richard F. Wallman is at least $32.01 million as of September 18th, 2023. Mr. Wallman owns 133,205 shares of Charles River Laboratories International stock worth more than $32,007,829 as of April 23rd. This net worth approximation does not reflect any other assets that Mr. Wallman may own. Learn More about Richard F. Wallman's net worth.

How do I contact Richard F. Wallman?

The corporate mailing address for Mr. Wallman and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Richard F. Wallman's contact information.

Has Richard F. Wallman been buying or selling shares of Charles River Laboratories International?

Richard F. Wallman has not been actively trading shares of Charles River Laboratories International during the past quarter. Most recently, on Thursday, August 24th, Richard F. Wallman bought 1,000 shares of Charles River Laboratories International stock. The stock was acquired at an average cost of $198.79 per share, with a total value of $198,790.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $198,790. Learn More on Richard F. Wallman's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, Charles River Laboratories International insiders bought shares 3 times. They purchased a total of 7,942 shares worth more than $1,447,729.04. During the last year, insiders at the medical research company sold shares 7 times. They sold a total of 23,211 shares worth more than $5,481,396.41. The most recent insider tranaction occured on February, 29th when EVP Victoria L Creamer sold 5,000 shares worth more than $1,268,500.00. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 2/29/2024.

Richard F. Wallman Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2023Buy1,000$198.79$198,790.001,000View SEC Filing Icon  
11/2/2020Buy1,150$232.96$267,904.0031,715View SEC Filing Icon  
7/29/2016Sell7,740$88.00$681,120.0024,190View SEC Filing Icon  
5/13/2016Sell1,970$82.32$162,170.4017,690View SEC Filing Icon  
5/10/2016Sell11,990$84.00$1,007,160.0027,420View SEC Filing Icon  
5/6/2016Sell2,720$81.00$220,320.0015,430View SEC Filing Icon  
8/12/2014Sell3,240$58.20$188,568.00View SEC Filing Icon  
See Full Table

Richard F. Wallman Buying and Selling Activity at Charles River Laboratories International

This chart shows Richard F Wallman's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $240.29
Low: $236.22
High: $242.91

50 Day Range

MA: $253.87
Low: $220.24
High: $273.43

2 Week Range

Now: $240.29
Low: $161.65
High: $275.00

Volume

485,088 shs

Average Volume

546,839 shs

Market Capitalization

$12.38 billion

P/E Ratio

26.09

Dividend Yield

N/A

Beta

1.4